New Label Expansion in Generalized Myasthenia Gravis - Poll - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

New Label Expansion in Generalized Myasthenia Gravis

Phase 3 ADAPT SERON data supported efgartigimod use across antibody subtypes often underrepresented in trials.

  • By

  • Kathryn Wighton

  • May 11, 2026

  • 2 min

Share

Original Source(s)

New Label Expansion in Generalized Myasthenia Gravis

  • by Kathryn Wighton

  • May 11, 2026

Related Content

Top 10 Evidence-Based Essentials in Neurology

A structured framework of guidelines, trials, therapies, and tools used in clinical practice.

FDA Clears Exoskeleton for Spinal Cord Injury

Use is limited to level indoor and adjoining outdoor areas and requires supervision by a companion with specialized training.

When Bad Data Enters the Drug Pipeline

Federal prosecutors allege that a Florida physician and research staff fabricated clinical trial records that were submitted into database systems used to evaluate investigational drugs.